British Journal of Cancer - Table of Contents alert Volume 106 Issue 5

TABLE OF CONTENTS Volume 106, Issue 5 (793-1020) Published online 28 February 2012 In this issue Clinical Studies Translational Therapeutics Molecular Diagnostics Epidemiology Also new today Advance online publication Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement British Journal of Cancer presents: The Fraction of Cancer Attributable to Lifestyle and Environmental Factors in the UK in 2010 The papers in this supplement estimate the percentage of cancers occurring in the UK in 2010 that were the result of exposure to common and for the most part modifiable lifestyle, dietary and environmental factors, providing a firm background for making individual lifestyle and public health policy decisions. Read the articles for FREE   Clinical Studies Top A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer N Steele, A Anthony, M Saunders, B Esmarck, E Ehrnrooth, P E G Kristjansen, A Nihlén, L T Hansen and J Cassidy Br J Cancer 2012 106: 793-798; advance online publication, February 7, 2012; 10.1038/bjc.2011.599 Abstract | Full Text Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients M Scartozzi, R Giampieri, E Maccaroni, M Del Prete, L Faloppi, M Bianconi, E Galizia, C Loretelli, L Belvederesi, A Bittoni and S Cascinu Br J Cancer 2012 106: 799-804; advance online publication, February 7, 2012; 10.1038/bjc.2012.17 Abstract | Full Text Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy L Sharp, L Tilson, S Whyte, A O'Ceilleachair, C Walsh, C Usher, P Tappenden, J Chilcott, A Staines, M Barry and H Comber Br J Cancer 2012 106: 805-816; advance online publication, February 16, 2012; 10.1038/bjc.2011.580 Abstract | Full Text Long-term CIN3+ risk in women with abnormal cytology; role of hrHPV testing M Kocken, J Berkhof, F J van Kemenade, J A Louwers, A Zaal, M A E Nobbenhuis, G Kenter, P J F Snijders, C J L M Meijer and T J M Helmerhorst Br J Cancer 2012 106: 817-825; advance online publication, February 14, 2012; 10.1038/bjc.2012.5 Abstract | Full Text Direct improvement of quality of life using a tailored quality of life diagnosis and therapy pathway: randomised trial in 200 women with breast cancer M Klinkhammer-Schalke, M Koller, B Steinger, C Ehret, B Ernst, J C Wyatt, F Hofstädter and W Lorenz for the Regensburg QoL Study Group Br J Cancer 2012 106: 826-838; advance online publication, February 7, 2012; 10.1038/bjc.2012.4 Abstract | Full Text A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer A A Chiappori, M T Schreeder, M M Moezi, J J Stephenson, J Blakely, R Salgia, Q S Chu, H J Ross, D S Subramaniam, J Schnyder and M S Berger Br J Cancer 2012 106: 839-845; advance online publication, February 14, 2012; 10.1038/bjc.2012.21 Abstract | Full Text Cancer stem cell phenotype relates to radio-chemotherapy outcome in locally advanced squamous cell head–neck cancer M I Koukourakis, A Giatromanolaki, V Tsakmaki, V Danielidis and E Sivridis Br J Cancer 2012 106: 846-853; advance online publication, February 14, 2012; 10.1038/bjc.2012.33 Abstract | Full Text Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents C Le Tourneau, V Servois, V Diéras, L Ollivier, P Tresca and X Paoletti Br J Cancer 2012 106: 854-857; advance online publication, January 26, 2012; 10.1038/bjc.2012.10 Abstract | Full Text Translational Therapeutics Top The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models S V Holt, A Logié, R Odedra, A Heier, S P Heaton, D Alferez, B R Davies, R W Wilkinson and P D Smith Br J Cancer 2012 106: 858-866; advance online publication, February 16, 2012; 10.1038/bjc.2012.8 Abstract | Full Text Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules T Shimokawa, M Seike, C Soeno, H Uesaka, A Miyanaga, H Mizutani, K Kitamura, Y Minegishi, R Noro, T Okano, A Yoshimura and A Gemma Br J Cancer 2012 106: 867-875; advance online publication, February 14, 2012; 10.1038/bjc.2012.7 Abstract | Full Text Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma K Hirashima, Y Baba, M Watanabe, R-I Karashima, N Sato, Y Imamura, Y Nagai, N Hayashi, K-I Iyama and H Baba Br J Cancer 2012 106: 876-882; advance online publication, February 14, 2012; 10.1038/bjc.2012.36 Abstract | Full Text Molecular Diagnostics Top Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10 H Modjtahedi, S A Khelwatty, R S Kirk, A M Seddon, S Essapen, C A Del Vecchio, A J Wong and S Eccles Br J Cancer 2012 106: 883-888; advance online publication, February 7, 2012; 10.1038/bjc.2012.27 Abstract | Full Text Cytochrome-c mediated a bystander response dependent on inducible nitric oxide synthase in irradiated hepatoma cells M He, S Ye, R Ren, C Dong, Y Xie, D Yuan and C Shao Br J Cancer 2012 106: 889-895; advance online publication, January 24, 2012; 10.1038/bjc.2012.9 Abstract | Full Text Supernatants derived from chemotherapy-treated cancer cell lines can modify angiogenesis W M Liu, J L Dennis, A M Gravett, C Chanthirakumar, E Kaminska, G Coulton, D W Fowler, M Bodman-Smith and A G Dalgleish Br J Cancer 2012 106: 896-903; advance online publication, January 31, 2012; 10.1038/bjc.2012.13 Abstract | Full Text Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis M de Martino, K Hoetzenecker, H J Ankersmit, G A Roth, A Haitel, M Waldert and T Klatte Br J Cancer 2012 106: 904-908; advance online publication, January 31, 2012; 10.1038/bjc.2012.20 Abstract | Full Text Circulating sphingosine-1-phosphate and erythrocyte sphingosine kinase-1 activity as novel biomarkers for early prostate cancer detection J Nunes, M Naymark, L Sauer, A Muhammad, H Keun, J Sturge, J Stebbing, J Waxman and D Pchejetski Br J Cancer 2012 106: 909-915; advance online publication, February 7, 2012; 10.1038/bjc.2012.14 Abstract | Full Text Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification A S Betof, Z N Rabbani, M E Hardee, S J Kim, G Broadwater, R C Bentley, S A Snyder, Z Vujaskovic, E Oosterwijk, L N Harris, J K Horton, M W Dewhirst and K L Blackwell Br J Cancer 2012 106: 916-922; advance online publication, February 14, 2012; 10.1038/bjc.2012.32 Abstract | Full Text Clinical significance of CD151 overexpression in subtypes of invasive breast cancer M J Kwon, S Park, J Y Choi, E Oh, Y J Kim, Y-H Park, E Y Cho, M J Kwon, S J Nam, Y-H Im, Y K Shin and Y-L Choi Br J Cancer 2012 106: 923-930; advance online publication, January 31, 2012; 10.1038/bjc.2012.11 Abstract | Full Text A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer J Eberhard, A Gaber, S Wangefjord, B Nodin, M Uhlén, K Ericson Lindquist and K Jirström Br J Cancer 2012 106: 931-938; advance online publication, February 14, 2012; 10.1038/bjc.2012.34 Abstract | Full Text Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level K Sakaizawa, Y Goto, Y Kiniwa, A Uchiyama, K Harada, S Shimada, T Saida, S Ferrone, M Takata, H Uhara and R Okuyama Br J Cancer 2012 106: 939-946; advance online publication, January 26, 2012; 10.1038/bjc.2012.12 Abstract | Full Text Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma H Miyagaki, M Yamasaki, H Miyata, T Takahashi, Y Kurokawa, K Nakajima, S Takiguchi, Y Fujiwara, H Ishii, F Tanaka, M Mori and Y Doki Br J Cancer 2012 106: 947-954; advance online publication, February 14, 2012; 10.1038/bjc.2012.35 Abstract | Full Text Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer P Kelly, F Paulin, D Lamont, L Baker, S Clearly, D Exon and A Thompson Br J Cancer 2012 106: 955-961; advance online publication, January 31, 2012; 10.1038/bjc.2012.15 Abstract | Full Text Epidemiology Top Population-based cancer incidence in Sikkim, India: report on ethnic variation Y Verma, P K Pradhan, N Gurung, S D Sapkota, P Giri, P Sundas, B N Bhattarai, D Nadayil, T Ramnath and A Nandakumar Br J Cancer 2012 106: 962-965; advance online publication, January 12, 2012; 10.1038/bjc.2011.598 Abstract | Full Text Exposure to animals and increased risk of marginal zone B-cell lymphomas of the ocular adnexae R Dolcetti, D Serraino, G Dognini, S Govi, R Crocchiolo, P Ghia, E Pasini, M Ponzoni, R Talamini, P De Paoli, C Doglioni and A J M Ferreri Br J Cancer 2012 106: 966-969; advance online publication, January 24, 2012; 10.1038/bjc.2012.2 Abstract | Full Text Skin cancer screening participation and impact on melanoma incidence in Germany – an observational study on incidence trends in regions with and without population-based screening A Waldmann, S Nolte, M A Weinstock, E W Breitbart, N Eisemann, A C Geller, R Greinert, B Volkmer and A Katalinic Br J Cancer 2012 106: 970-974; advance online publication, January 31, 2012; 10.1038/bjc.2012.22 Abstract | Full Text HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications D C Rijkaart, J Berkhof, F J van Kemenade, V M H Coupe, L Rozendaal, D A M Heideman, R H M Verheijen, S Bulk, W Verweij, P J F Snijders and C J L M Meijer Br J Cancer 2012 106: 975-981; advance online publication, January 17, 2012; 10.1038/bjc.2011.581 Abstract | Full Text Features of childhood cancer in primary care: a population-based nested case–control study R M Dommett, M T Redaniel, M C G Stevens, W Hamilton and R M Martin Br J Cancer 2012 106: 982-987; advance online publication, January 12, 2012; 10.1038/bjc.2011.600 Abstract | Full Text Socioeconomic position, treatment, and survival of non-Hodgkin lymphoma in Denmark – a nationwide study B L Frederiksen, S O Dalton, M Osler, M Steding-Jessen and P de Nully Brown Br J Cancer 2012 106: 988-995; advance online publication, February 7, 2012; 10.1038/bjc.2012.3 Abstract | Full Text Relationship between breast cancer risk factors and mammographic breast density in the Fernald Community Cohort L Yaghjyan, M C Mahoney, P Succop, R Wones, J Buckholz and S M Pinney Br J Cancer 2012 106: 996-1003; advance online publication, January 26, 2012; 10.1038/bjc.2012.1 Abstract | Full Text Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition S Rohrmann, V A Grote, S Becker, S Rinaldi, A Tjønneland, N Roswall, H Grønbæk, K Overvad, M C Boutron-Ruault, F Clavel-Chapelon, A Racine, B Teucher, H Boeing, D Drogan, V Dilis, P Lagiou, A Trichopoulou, D Palli, G Tagliabue, R Tumino, P Vineis, A Mattiello, L Rodríguez, E J Duell, E Molina-Montes, M Dorronsoro, J-M Huerta, E Ardanaz, S Jeurnink, P H M Peeters, B Lindkvist, D Johansen, M Sund, W Ye, K-T Khaw, N J Wareham, N E Allen, F L Crowe, V Fedirko, M Jenab, D S Michaud, T Norat, E Riboli, H B Bueno-de-Mesquita and R Kaaks Br J Cancer 2012 106: 1004-1010; advance online publication, February 7, 2012; 10.1038/bjc.2012.19 Abstract | Full Text Gallstones and cholecystectomy in relation to risk of intra- and extrahepatic cholangiocarcinoma H Nordenstedt, F Mattsson, H El-Serag and J Lagergren Br J Cancer 2012 106: 1011-1015; advance online publication, January 12, 2012; 10.1038/bjc.2011.607 Abstract | Full Text Malignant mesotheliomas in former miners and millers of crocidolite at Wittenoom (Western Australia) after more than 50 years follow-up G Berry, A Reid, P Aboagye-Sarfo, N H de Klerk, N J Olsen, E Merler, P Franklin and A W Musk Br J Cancer 2012 106: 1016-1020; advance online publication, February 7, 2012; 10.1038/bjc.2012.23 Abstract | Full Text Advertisement British Journal of Cancer presents: Web Focus on MicroRNA MicroRNAs have emerged as major new mechanisms of regulation of gene function, potential therapeutic targets, with roles in diagnosis, prognosis and biomarkers. This collection puts MicroRNA in context of other molecular classifications and then investigative articles and reviews cover the main tumour types where microRNAs are emerging as having important roles in biological processes including lung cancer, AML, melanoma, colorectal cancer, nasopharyngeal carcinoma, bladder cancer, rhabdomyosarcoma and heptacellular carcinoma. Read the articles for FREE   Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.